Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.76)
# 780
Out of 4,670 analysts
149
Total ratings
56.67%
Success rate
39.88%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $14.70 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $18.54 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $738.00 | +15.18% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.41 | +1,176.60% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $4.03 | +1,388.83% | 3 | Sep 7, 2023 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Overweight | $16 | $59.80 | -73.24% | 5 | Aug 22, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $4.01 | +124.44% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $4.00 | +750.00% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $157.90 | +107.09% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $6.04 | +396.69% | 4 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $71 | $1.08 | +6,474.07% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $450.97 | -37.69% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.88 | +325.53% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $2.29 | +4,179.48% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $294.53 | +0.16% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $90.19 | -4.65% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $35.07 | +36.87% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $20.54 | +46.06% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $55.68 | +29.31% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.80 | +177.78% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $71.72 | +39.43% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $28 → $24 | $0.33 | +7,284.62% | 3 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $129.81 | +54.84% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $43.23 | +96.62% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $8.86 | +261.17% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $114.23 | +89.97% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $22.27 | +115.54% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $10.11 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $244.89 | -37.11% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $64.26 | +80.52% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.00 | +3,433.33% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $14.30 | +95.80% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $167.69 | -51.10% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $372.89 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.38 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.70
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.54
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $738.00
Upside: +15.18%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.41
Upside: +1,176.60%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $4.03
Upside: +1,388.83%
Longboard Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $59.80
Upside: -73.24%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $4.01
Upside: +124.44%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $4.00
Upside: +750.00%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $157.90
Upside: +107.09%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $6.04
Upside: +396.69%
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $1.08
Upside: +6,474.07%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $450.97
Upside: -37.69%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.88
Upside: +325.53%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $2.29
Upside: +4,179.48%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $294.53
Upside: +0.16%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $90.19
Upside: -4.65%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $35.07
Upside: +36.87%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $20.54
Upside: +46.06%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $55.68
Upside: +29.31%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.80
Upside: +177.78%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $71.72
Upside: +39.43%
May 5, 2020
Reiterates: Overweight
Price Target: $28 → $24
Current: $0.33
Upside: +7,284.62%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $129.81
Upside: +54.84%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $43.23
Upside: +96.62%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $8.86
Upside: +261.17%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $114.23
Upside: +89.97%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $22.27
Upside: +115.54%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $10.11
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $244.89
Upside: -37.11%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $64.26
Upside: +80.52%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.00
Upside: +3,433.33%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $14.30
Upside: +95.80%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $167.69
Upside: -51.10%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $372.89
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.38
Upside: -